BMS-986416

N/A

Report date: 2025/05/22 15:16:53

Base Information

Drug NameBMS-986416
Drug Alias NameTGFβ receptor ectodomain-IgG Fc fusion proteinAVID-200BMS-986416AVID-200 DP
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTransforming growth factor beta 3 inhibitorsTransforming growth factor beta 1 inhibitors
TargetsTransforming growth factor beta 3Transforming growth factor beta 1
Therapy Area/IndicationsSolid tumoursScleroderma, DiffusePrimary Myelofibrosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[7] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesFormation Biologics Corp
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyFormation Biologics CorpJohn Mascaren As
Inactive CompaniesN/A
Active IndicationsSolid tumoursPrimary MyelofibrosisThrombocythemia, Essential +[4] 
Inactive IndicationsScleroderma, Diffuse

Other Information

ATC CodeN/A
Related LinksN/A